Illumina 27 feb 2026 Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - The Korea Herald
Illumina 26 feb 2026 SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings - the-scientist.com
Illumina 26 feb 2026 Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Illumina 26 feb 2026 SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings - News-Medical
Illumina 25 feb 2026 Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics - PR Newswire
Illumina 25 feb 2026 How Illumina multiomics helps scientists track elusive ovarian cancers - Stock Titan
Illumina 25 feb 2026 Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Illumina 25 feb 2026 Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility - Yahoo Finance
Illumina 24 feb 2026 Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina 24 feb 2026 Illumina launches TruPath Genome, setting a new standard in genomic insight - PR Newswire
Illumina 24 feb 2026 Illumina's TruPath Genome offers rapid whole genome testing for rare disease - Stock Titan
Illumina 24 feb 2026 The Bull Case For Illumina (ILMN) Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why - simplywall.st
Illumina 23 feb 2026 Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews
Illumina 23 feb 2026 Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility - PR Newswire
Illumina 23 feb 2026 Faster DNA decoding: Illumina’s NovaSeq X gets 40% more data, higher accuracy - Stock Titan